An observational study in Homozygous Familial Hypercholesterolemia (HoFH), Major Adverse Cardiovascular Events (MACE) and Dyslipidemia, sponsored by Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi). Active, not recruiting at 30 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Homozygous Familial Hypercholesterolemia with a site in Italy — 2 open to participants now, 3 under way, 1 of them phase 3. Homozygous Familial Hypercholesterolemia · Italy.
Among the 15 studies in Homozygous Familial Hypercholesterolemia with a site in Italy, this one is the only one that started in 2024, is one of 3 observational ones, and was the 14th registered.
68 studies on the registry are indexed under Homozygous Familial Hypercholesterolemia; 13 are open to participants now.
Browse Homozygous Familial Hypercholesterolemia studies →2 of the 15 studies in Homozygous Familial Hypercholesterolemia with a site in Italy are open now. Recruiting first, the newest first:
Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi) · Sites in Italy, France, Netherlands and 1 more country
Ages 12+
Novartis Pharmaceuticals · Sites in Italy, United States, Argentina and 23 more countries
Ages 2–100
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 12 Homozygous Familial Hypercholesterolemia studies recruiting now, 6 (50%) set no upper age limit and 5 (42%) stop at 75 or younger; 8 take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 10
First in 2007; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 73 is below the median of 167 across 14 observational studies indexed under Homozygous Familial Hypercholesterolemia.
Median enrollment 62 across the 12 interventional studies, 73 across the 3 observational. Of the 12 that completed or were terminated, 10 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 15 have an industry lead sponsor. The 8 most frequent:
Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi) is the lead sponsor of 5 studies on the registry; 3 are open to participants now.
Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi) has 2 studies filed under Homozygous Familial Hypercholesterolemia — fewer than ten, so there is no comparison to draw.
1 of the studies in Homozygous Familial Hypercholesterolemia with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07447648Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi)Assessing the Impact of Intensification of Lipid Lowering Therapy With Guidelines-based Evinacumab Administration on Coronary Plaque Volumes Measured by Coronary Computed Tomography Angiography (CCTA) in Patients With Homozygous Familial Hypercholesterolemia (HoFH) | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies in Homozygous Familial Hypercholesterolemia with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This observational, multicenter, retrospective and prospective study aims to evaluate the effect of lomitapide treatment on Major Adverse Cardiovascular Events (MACE) in patients with Homozygous Familial Hypercholesterolemia (HoFH).
HoFH is a rare genetic disorder characterized by extremely high levels of LDL cholesterol (LDL-C), leading to an increased risk of early cardiovascular diseases. Lomitapide is an approved medication that lowers LDL-C levels by inhibiting microsomal triglyceride transfer protein (MTP).
The study will collect data from patients who have been treated with lomitapide for at least 12 months and will compare the incidence of MACE during the first three years of treatment with the three years before treatment initiation. The study includes data collection from multiple lipid centers across Europe.
The primary objective is to assess the impact of lomitapide on MACE, while secondary objectives include evaluating changes in lipid profiles, liver function tests, and lipid-lowering treatments.
This is a multicenter, international, long-term observational study investigating the real-world impact of lomitapide on Major Adverse Cardiovascular Events (MACE) in patients with Homozygous Familial Hypercholesterolemia (HoFH).
Study Design:
Observational, open-label, retrospective and prospective study Data will be collected from 30 lipid centers across Europe Patients will serve as their own control, with comparisons between pre-treatment (3 years before lomitapide) and post-treatment (first 3 years of lomitapide therapy) periods
Study Population:
Approximately 72 adult patients (≥18 years) diagnosed with HoFH Patients must have received lomitapide for at least 12 months Availability of 3 years of pre-treatment clinical records
Objectives:
Primary Objective: Evaluate the incidence of MACE before and after lomitapide treatment
Secondary Objectives: Assess changes in LDL-C, total cholesterol, liver function tests (ALT, AST, GGT), and lipid-lowering therapy usage (e.g., discontinuation of LDL apheresis, addition of PCSK9 inhibitors)
Endpoints:
Primary Endpoint: Change in MACE incidence over the 3-year treatment period
Secondary Endpoints: Changes in lipid levels, liver safety markers, and adherence to treatment protocols
Safety Considerations:
The study follows real-world clinical practice, with monitoring of adverse events, including liver-related safety concerns associated with lomitapide
Data will be collected in an electronic Case Report Form (eCRF) and analyzed following Good Clinical Practice (GCP) guidelines
This study aims to generate real-world evidence on the cardiovascular impact of lomitapide in HoFH patients, addressing an unmet clinical need for data on long-term outcomes.
Patients with a clinical or genetic diagnosis of homozygous familial hypercholesterolemia (HoFH) who have been treated with lomitapide for at least 12 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This cohort consists of adult patients (≥18 years) diagnosed with Homozygous Familial Hypercholesterolemia (HoFH) who have been treated with lomitapide for at least 12 months. The study will retrospectively analyze the incidence of Major Adverse Cardiovascular Events (MACE) in the three years before lomitapide treatment, and prospectively track MACE incidence during the first three years of lomitapide therapy.
Incidence of Major Adverse Cardiovascular Events (MACE) Before and After Lomitapide Treatment
This measure will assess the incidence of MACE (including myocardial infarction, stroke, cardiovascular death, and hospitalization due to unstable angina) during the first three years of lomitapide treatment compared to the three years prior to treatment initiation. Unit of Measure: Number of events per 100 patient-years.
Time frame: 3 years before treatment vs. 3 years during treatment
Change in LDL-Cholesterol Levels
This measure will evaluate changes in LDL-C levels. Unit of Measure: mg/dL.
Time frame: Baseline, 1 year, 2 years, 3 years
Change in Total Cholesterol, Triglycerides, and HDL-Cholesterol
Assess changes in total cholesterol, triglycerides, and HDL-C at 1, 2, and 3 years after lomitapide treatment initiation. Unit of Measure: mg/dL.
Time frame: Baseline, 1 year, 2 years, 3 years
Change in Triglyceride Levels
This measure will evaluate changes in triglyceride levels. Unit of Measure: mg/dL.
Time frame: Baseline, 1 year, 2 years, 3 years.
Change in HDL-Cholesterol Levels
This measure will evaluate changes in HDL-C levels. Unit of Measure: mg/dL.
Time frame: Baseline, 1 year, 2 years, 3 years
Liver Safety Profile - ALT Levels
This measure will evaluate changes in alanine aminotransferase (ALT) levels. Unit of Measure: U/L.
Time frame: Baseline, 1 year, 2 years, 3 years.
Liver Safety Profile - AST Levels
This measure will evaluate changes in aspartate aminotransferase (AST) levels. Unit of Measure: U/L.
Time frame: Baseline, 1 year, 2 years, 3 years.
Liver Safety Profile - GGT Levels
This measure will evaluate changes in gamma-glutamyl transferase (GGT) levels. Unit of Measure: U/L.
Time frame: Baseline, 1 year, 2 years, 3 years.
Lipid-Lowering Therapy Modifications
This measure will track changes in lipid-lowering therapies, for example the discontinuation of LDL apheresis or the introduction of evinacumab, as described in the study protocol. Unit of Measure: Number of patients with therapy modifications.
Time frame: Baseline, 1 year, 2 years, 3 years.
Biomarkers of Liver and Vascular Damage
This measure will evaluate biomarkers of liver and vascular damage, including FIB4, apolipoprotein B, lipoprotein(a), cytokeratin 18 fragment (CK-18F), hematology, and other relevant markers. Unit of Measure: Laboratory values in mg/dL or U/L, as applicable.
Time frame: Baseline and after 3 years of lomitapide treatment.
Presence and Severity of Hepatic Steatosis
This measure will assess the presence and severity of hepatic steatosis using liver ultrasound or MRI. Severity will be graded as absent, mild, moderate, or severe. Unit of Measure: Qualitative assessment (absent, mild, moderate, severe).
Time frame: After 3 years of lomitapide treatment.
Liver Elastography Parameters
This measure will evaluate liver elastography parameters using fibroscan or other methods. Measurements will include liver stiffness (kPa) and controlled attenuation parameter (CAP) values. Unit of Measure: kPa (kilopascal) and CAP (dB/m).
Time frame: After 3 years of lomitapide treatment.
Dietary Records
This measure will evaluate dietary patterns using a food frequency questionnaire (FFQ) for patients participating in the prospective phase of the study. Unit of Measure: Responses to FFQ (categorical and quantitative data).
Time frame: After 3 years of lomitapide treatment.
Adherence to Lipid-Lowering Medications
This measure will evaluate adherence to lipid-lowering medications, including lomitapide, using a Medication Adherence Scale for patients participating in the prospective phase. Unit of Measure: Medication Adherence Scale scores.
Time frame: After 3 years of lomitapide treatment.
Plan to share: No — The LILITH study collects observational data on patients treated with lomitapide in compliance with data protection regulations (GDPR) and Good Clinical Practice (GCP) guidelines. At this time, individual participant data (IPD) sharing is not planned to ensure confidentiality and adherence to ethical and legal requirements. However, aggregated study results will be made available through scientific publications and regulatory reports.
No publications or documents are linked to this record.
Started Sep 2024 (actual). Primary completion is estimated for Feb 2028, 41 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 3, 2026: primary completion Dec 2026 → Feb 2028 and completion Dec 2026 → Feb 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Homozygous Familial Hypercholesterolemia →
Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi)